What is KeraNetics?
KeraNetics, Inc. operates at the intersection of regenerative medicine and oncology supportive care. By leveraging research partnerships with the Wake Forest Institute for Regenerative Medicine, the company has developed KeraStat Cream, an FDA-cleared medical device specifically engineered to manage radiation dermatitis. This condition, characterized by severe skin irritation and inflammation, affects a significant portion of patients receiving radiotherapy. KeraNetics provides a critical intervention that improves patient comfort and treatment adherence, positioning itself as a vital player in the supportive care ecosystem for healthcare providers and cancer centers globally.
How much funding has KeraNetics raised?
KeraNetics has raised a total of $5.5M across 3 funding rounds:
Private Equity
$3.4M
Debt
$1.9M
Debt
$150K
Private Equity (2015): $3.4M, investors not publicly disclosed
Debt (2017): $1.9M, investors not publicly disclosed
Debt (2020): $150K supported by PPP
Key Investors in KeraNetics
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
PPP
Public-Private Partnership
What's next for KeraNetics?
Looking ahead, KeraNetics is well-positioned to leverage its recent capital injection to accelerate market penetration and potentially diversify its product pipeline. As the company transitions from its initial development phases into a more mature commercial entity, the focus will likely shift toward scaling distribution channels and deepening its clinical evidence base. By maintaining its focus on high-impact regenerative solutions, KeraNetics is poised to address the growing demand for specialized dermatological care in oncology, ensuring that its strategic growth aligns with the evolving needs of the global radiotherapy market.
See full KeraNetics company page
